内容紹介
Clinical Efficacy of Alternate-Day S-1/Letrozole Combination Therapy for Advanced Breast Cancer with Gastric Metastasis―A Case Report
Summary
We report a case of StageⅣ breast cancer in a 62-year-old woman who responded well to alternate-day S-1/letrozole combination therapy. She was admitted to our hospital because of appetite loss and vomiting, and was diagnosed with invasive lobular carcinoma(ER+/HER2-)with gastric metastasis. After gastrointestinal stenting was performed, we initiated oral administration of S-1(100 mg/body)and letrozole(2.5 mg)as systemic therapy. To reduce adverse effects, we administered S-1 on alternate days. Computed tomography and endoscopic examination revealed that the patient has been showing partial response since 1 year after initiating treatment. Therefore, we conclude that alternate-day S-1/letrozole combination therapy could be an effective and sustainable treatment for advanced ER-positive, HER2-negative breast cancer.
要旨
症例は62歳,女性。食思不振,嘔吐を主訴に受診し,上部消化管内視鏡検査,CT検査,組織診検査にて胃転移を伴うestrogen receptor(ER)陽性,human epidermal growth factor receptor 2(HER2)陰性,浸潤性小葉癌と診断された。通過障害に対してステント留置後S-1隔日投与とletrozole併用を行ったところ著効し,1年以上にわたりPRを維持している。ER陽性・HER2陰性乳癌に対してS-1とletrozoleの併用は有望な選択肢であり,かつS-1隔日投与はさらに有害事象を抑えることでperformance status(PS)が低下した進行例でも安全に施行できる有用かつ継続可能な治療法と考えられる。
目次
Summary
We report a case of StageⅣ breast cancer in a 62-year-old woman who responded well to alternate-day S-1/letrozole combination therapy. She was admitted to our hospital because of appetite loss and vomiting, and was diagnosed with invasive lobular carcinoma(ER+/HER2-)with gastric metastasis. After gastrointestinal stenting was performed, we initiated oral administration of S-1(100 mg/body)and letrozole(2.5 mg)as systemic therapy. To reduce adverse effects, we administered S-1 on alternate days. Computed tomography and endoscopic examination revealed that the patient has been showing partial response since 1 year after initiating treatment. Therefore, we conclude that alternate-day S-1/letrozole combination therapy could be an effective and sustainable treatment for advanced ER-positive, HER2-negative breast cancer.
要旨
症例は62歳,女性。食思不振,嘔吐を主訴に受診し,上部消化管内視鏡検査,CT検査,組織診検査にて胃転移を伴うestrogen receptor(ER)陽性,human epidermal growth factor receptor 2(HER2)陰性,浸潤性小葉癌と診断された。通過障害に対してステント留置後S-1隔日投与とletrozole併用を行ったところ著効し,1年以上にわたりPRを維持している。ER陽性・HER2陰性乳癌に対してS-1とletrozoleの併用は有望な選択肢であり,かつS-1隔日投与はさらに有害事象を抑えることでperformance status(PS)が低下した進行例でも安全に施行できる有用かつ継続可能な治療法と考えられる。